Eczema of the Eyelids and Screening for Eye Damage in Atopic Dermatitis

1. AMIN, K. A., BELSITO, D. V. The aetiology of eyelid dermatitis: a 10-year retrospective analysis. ContactDermatitis, 2006, 55, p. 280–285.
2. ASSIER, H., TETART, F., AVENEL-AUDRAN, M. et al. Is a specfic eyelid patch test series usefull? Contact Dermatitis, 2018, 79, p. 157–161.
3. AYALA, F., FABBROCINI, G., BACCHILEGA, R. et al. Eyelid dermatitis: an evaluation of 447 patients. Am J Contact Dermat, 2003, 14, p. 69–74.
4. BANSAL, A., SIMPSON, E. L., PALLER, A. S. et al. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. American Journal of Clinical Dermatology, 2021, 22, p. 101–115.
5. BECK, K. M., SEITZMAN, G. D., YANG, E. J. et al. Ocular CoMorbidities of Atopic Dermatitis. Am J Clin Dermatol, 2019, 20, p. 797−805 (Part I), p. 807–815 (Part II).
6. BENAIM, D., TÉTART, F., BAUVIN, O. et al. Tacrolimus ointment in the management of atopic keratoconjunctivitis. J Fr Ophtalmol, 2019, 42, p. 435–440.
7. CALLOU, T. M. P., ORFALI, R. M., SOTTO, M. N. et al. Increase expression of filaggrin and claudin1 in the ocular surface of patients with atopic dermatitis. JEADV, 2022, 36, p. 247–254.
8. CARMI, E., DEFOSSEZ-TRIBOUT, C., GANRY, O. et al. Ocular complications of atopic dermatitis in children. Acta Derm Venereol, 2006, 86, p. 515–517.
9. DAVIS, D. M. R., DRUCKER, A. M., ALIKHAN, A. et al. American Academy of Dermatology Guidelines: awareness of comorbidities associated with atopic dermatitisin adults. J Am Acad Dermatol, 2022, 86, p. 1335–1336.
10. DROITCOURT, C., TOUBOUL, D., GED, C. et al. A prospective study of filaggrin null mutations in keratoconus patients with or without atopic disorders. Dermatology, 2011, 222, p. 336–341.
11. FESER, A., PLAZA, T., VOGELSANG, L., MAHLER, V. Perirobital dermatitis – a recalcitrant disease: causes and differential diagnosis. Br J Dermatol, 2008, 159, p. 858–863.
12. HIROTA, A., SHOJI, J., INADA, N., SHIRAKI, Y., YAMAGAMI, S. Evaluation of clinical efficacy and safety of prolonged treatment of vernal and atopickeratoconjunctivitis using topical tacrolimus. Cornea, 2022, 41, p. 23–30.
13. HUANG, C. X., YANNIAS, J. A., Killian, J. M. et al. Seven Common Allergen Groups Causing Eyelid Dermatitis: Education and Avoidance Strategies, Clinical Ophthalmology, 2021, 15, p. 1477–1490.
14. HORNER, M. E. et al. The spectrum of oculocutaneous disease. Part I. JAAD, 2014, 795, e1–25
15. HSU, I. H., PFLUGFELDER, S. C., KIM, S. J. Ocular complications of atopic dermatitis. Cutis, 2019, 104, p. 189–193.
16. KIMURA, A., TAKEDA, A., IKEBUKURO, T., HORI, J. Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. JOphthalmic Inflamm Infect., 2021, 11, p. 3.
17. LIN, T. Y., WANG, C. Y, WANG, F. Y. et al. Association between dupilumab and conjunctivitis. Pharmaceutics2023,15, p. 1031. doi: https://doi.org/10.3390/ pharmaceutics15041031.
18. LYLES, J., ROTHENBERG, M. Role of genetics, environment, and their interactions in the pathogenesis of eosinophilic esophagitis. Curr Opin Immunol, 2019, 60, p. 46–53.
19. NEČAS, M., DASTYCHOVÁ, E. Periorbital contact allergic dermatitis – the most common allergens in the Czech Republic. Int J Ophthalmol Clin Res, 2017, 4, 074.
20. ONGUCHI, T., DOGRU, M., OKADA, N. et al. The impact of the onset time of atopic keratoconjunctivitis on the tear function and ocular surface findings. Am J Ophthalmol, 2006, 141, p. 569–571.
21. PIETRUSZYŃSKA, M., ZAWADZKA-KRAJEWSKA, A., DUDA, P. et al. Ophthalmic manifestations of atopic dermatitis. Postepy Dermatol Alergol, 2020, 37, p. 174–179.
22. RØNNSTAD, A. T. M., HANSEN, P. M., HALLING, A. S. et al. Factors associated with ocular surface disease and severity in adults with atopic dermatitis: a nationwide survey. JEADV, 2022, 36, p. 592–601.
23. TÁNCZOSOVÁ, M., SKALICKÁ P., GKALPAKIOTIS, S. Oční komorbidity u atopické dermatitidy a kazuistika pacienta se závažnými očními komplikacemi léčeného dupilumabem. Remedia, 2020, 31.
24. THYSSEN, J. P., TOFT, P. B., HALLING-OVERGAARD, A. S. et al. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. JAAD, 2017, 77, p. 280–286.
25. THYSSEN,  J.  P.,  HALLING-OVERGAARD,  A.  S., SCHMID-GRENDELMEIER, P. et al. Comorbidities of atopic dermatitis – what does the evidence say ? JAllergy Clin Imunol., 2023, in press. doi: https://doi. org/10.1016/j.jaci.2022.12.002.
26. WARSHAW, E. M., VOLLER, I. M., MAIBACH, H. I. et al. Eyelid dermatitis in patients referred for patch testing: retrospective analysis of North American Contact Dermatitis Group data, 1994–2016. JAAD, 2021, 84, p. 953–964.
27. WESTLAND, T., DE BRUIN-WELLER, M. S., VAN DERLELIJ, A. Treatment of atopic keratoconjunctivitis in patients with atopic dermatitis: is ocular application of tacrolimus an option? JEADV, 2013, 27, p.187–189.
28. FARD, S. Ophtalmologic manifestation of atopic dermatitis. Medscape, 2022. Dostupné na www: https://emedicine.medscape.com/article/1197636-overview.

Konflikt zájmů

Autorka prohlašuje, že nemá v souvislosti se zpracovaným tématem konflikt zájmů.

Poděkování

Poděkování patří paní as. MUDr. P. Skalické, Ph.D., z Centra pro onemocnění spojivky a rohovky Oční kliniky LF UK a VFN v Praze za poskytnutí fotodokumentace a také recenzentům za cenné rady.

Do redakce došlo dne 31. 10. 2023.

Adresa pro korespondenci:
MUDr. Nina Benáková, Ph.D.
Dermatoalergologie Immuno Flow,
Rychnovská 681
199 00 Praha 9
e-mail: nina.benakova@email.cz